Abstract 977
Background
To examine the effectiveness of an advance care planning (ACP) intervention in facilitating concordance between cancer patients’ preferred and life-sustaining treatments (LSTs) received in the last month and in improving quality of life (QOL), anxiety symptoms, and depressive symptoms over the dying process.
Methods
Terminally ill cancer patients (N = 460) were randomly assigned 1:1 to the experimental and control arms. Data were obtained from 430 participants who died through December 2017. The experimental arm received an individualized, interactive ACP intervention tailored to participants’ readiness to engage in ACP. The control arm received a sham intervention of education on symptom management. Group allocation was concealed, data collectors were blinded, and treatment fidelity was ensured. Outcome measures included concordance of preferences for and receipt of six LSTs, QOL (McGill Quality of Life Questionnaire scores), as well as anxiety and depressive symptoms (Hospital Anxiety and Depression Scale scores). Intervention effectiveness was evaluated by intention-to-treat analysis.
Results
Concordance between LST preferences and LSTs received were 58.2-77.5% and 59.0-75.7% for the experimental and control arms, respectively. Between-arm differences in concordance between the six preferred and received LSTs were not significantly (odds ratios [95% CI]: 0.966 [0.653, 1.428]-1.107 [0.690, 1.775]). Participants in the experimental arm had significantly lower anxiety (β [95% CI]=-0.583 [-0.977, -0.189], p = 0.004) and depressive (β [95% CI]=-0.533 [-1.036, -0.030], p = 0.038) symptoms than those in the control arm, but QOL did not differ.
Conclusions
Our individualized, and interactive ACP intervention facilitated participants’ psychological adjustment to the end-of-life (EOL)-care decision-making process, but did not improve their QOL nor facilitate EOL care that honored their wishes before death. Our findings can ensure clinicians that ACP intervention is not detrimental to patients’ psychological well-being, but improves it at EOL.
Clinical trial identification
NCT01912846, 2018/1/24.
Legal entity responsible for the study
Chang Gung University, School of Nursing.
Funding
National Health Research Institutes in Taiwan.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract